Description

CJC no DAC 10MG

We provide CJC 1295 no DAC as a 10MG research peptide with a stated 99.1% purity. Furthermore, this material represents a modified 29-amino-acid growth hormone-releasing hormone analog associated with pituitary GHRH receptor signaling and growth hormone secretion. Consequently, researchers can investigate its relationship with somatotroph activity, cAMP-linked signaling, and the broader GH–IGF-1 axis. Research on GHRH analogs has demonstrated their ability to influence GH and IGF-1 secretion under controlled experimental conditions.

CJC no DAC Key Attributes

• Brand: AvigenLab
• Product Name: CJC no DAC
• Quantity: 10MG
• Stated Purity: 99.1%
• Molecular Type: Modified GHRH Analog
• Peptide Length: 29 Amino Acids
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

CJC no DAC Product Overview

We provide CJC no DAC for research involving growth hormone secretion, GHRH receptor activity, pituitary somatotroph signaling, cAMP-associated pathways, and IGF-1 regulation. Moreover, CJC-1295-related research has demonstrated stimulation of GH and IGF-1 secretion, while studies of GHRH analogs have examined their interaction with pituitary growth hormone-releasing mechanisms.

Additionally, the absence of the drug-affinity-complex modification distinguishes the no-DAC configuration from long-acting CJC-1295 formulations designed to bind endogenous albumin. Therefore, researchers can distinguish the two configurations according to their structural characteristics and pharmacological behavior.

Explore additional research materials through our Online Store.

CJC no DAC Product Identification

We identify CJC no DAC through its defined 10MG quantity, modified GHRH analog classification, stated 99.1% purity, and vial presentation. Furthermore, PubChem lists a 29-residue peptide structure for the compound and provides a molecular weight of approximately 3,367.9 g/mol for the listed structure.

Accordingly, the peptide length, molecular identity, quantity, purity designation, and physical format provide clear reference points for laboratory documentation and inventory management.

Product Category

We classify the material within our research peptide collection for endocrine, pituitary, growth hormone, and growth-factor investigations. Moreover, GHRH analog research provides an established scientific foundation for examining how modified peptides interact with pituitary receptors and influence downstream hormonal signaling.

Furthermore, experimental research has shown that GHRH-related analogs can stimulate GH secretion in cultured pituitary cells and animal models. Consequently, the material remains relevant to controlled investigations into somatotroph function and endocrine signaling.

Scientific Characteristics

The material represents a modified 29-amino-acid GHRH analog rather than a naturally occurring peptide. In particular, the no-DAC configuration differs from CJC-1295 formulations that incorporate a drug-affinity complex capable of promoting albumin binding and substantially extending circulating exposure.

Furthermore, GHRH receptor activation connects with intracellular signaling pathways that regulate pituitary GH secretion. Meanwhile, downstream GH activity can influence circulating IGF-1, creating an interconnected research framework spanning receptor activation, hormone release, and growth-factor signaling.

Research Applications

We position CJC no DAC for research involving GHRH receptor signaling, growth hormone secretion, pituitary somatotroph activity, cAMP-associated signaling, IGF-1 regulation, and endocrine physiology.

Additionally, researchers have investigated GHRH analogs through cultured pituitary cells and animal models, where these compounds stimulated measurable GH responses. Likewise, human research involving CJC-1295 demonstrated increases in mean GH and IGF-1 concentrations while preserving the pulsatile character of GH secretion.

Nevertheless, researchers should distinguish findings associated with long-acting DAC-containing CJC-1295 from findings involving the shorter-acting no-DAC configuration. Therefore, experimental results require interpretation according to the specific molecular formulation, research model, and measured endpoint.

Product Configuration

We provide CJC no DAC in a 10MG vial carrying a stated 99.1% purity designation. Accordingly, the defined quantity, peptide classification, purity specification, and physical presentation establish straightforward reference points for laboratory inventory.

Furthermore, the vial configuration distinguishes this presentation from combination products containing Ipamorelin and from other growth-hormone-related research materials. Consequently, researchers can organize the material according to its individual peptide identity and defined product format.

Product Features

The primary features include a 10MG quantity, 99.1% stated purity, modified GHRH analog composition, and clearly defined research-use presentation. Additionally, the product label communicates Not For Human Use | Research Use Only.

Moreover, the molecular profile connects the material with pituitary GHRH signaling and growth hormone research. As a result, researchers can use the material as a defined subject when investigating receptor-mediated endocrine pathways under controlled laboratory conditions.

CJC no DAC Product Specifications

PubChem identifies the listed CJC-1295 without DAC structure as a 29-residue peptide with a calculated molecular weight of approximately 3,367.9 g/mol.

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than therapeutic or consumer applications.

In particular, researchers can examine the compound within experimental systems involving pituitary receptor signaling, GH secretion, GHRH biology, and IGF-1-axis regulation. Furthermore, research involving related CJC-1295 structures has demonstrated measurable effects on GH and IGF-1 secretion in controlled human studies.

Nevertheless, results obtained from DAC-containing CJC-1295 cannot automatically establish equivalent pharmacokinetic or biological behavior for every no-DAC formulation. Therefore, researchers should evaluate each preparation according to its specific structure and experimental characteristics.

Packaging Information

We present the product in a clearly labeled 10MG vial featuring our AvigenLab product presentation. The packaging communicates the 10MG quantity, displays the stated 99.1% Purity, and identifies the material as Not For Human Use | Research Use Only.

Additionally, the vial format provides straightforward identification within our research catalog. You can also explore our broader Catalog for related research materials.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, published studies concerning CJC-1295 or related GHRH analogs do not constitute regulatory approval for this specific AvigenLab presentation.

Moreover, a 2026 review highlights ongoing uncertainty surrounding unregulated peptides marketed for GH–IGF-1-axis modulation, including CJC-1295 without DAC. Consequently, we focus our documentation on molecular characteristics, research relevance, product specifications, and published evidence rather than presenting experimental findings as established therapeutic outcomes.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters.

Furthermore, researchers should maintain appropriate laboratory handling practices and follow the product-specific documentation associated with the material. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our CJC no DAC 10MG presentation provides a defined individual research peptide configuration within our product collection. The quantity, stated purity, 29-amino-acid classification, vial format, and Research Use Only designation create clear reference points for laboratory inventory.

Moreover, CJC-1295-related research has established a substantial history within endocrine and growth-factor science. Likewise, experimental studies have investigated GHRH analog activity in pituitary cells, animals, and human subjects, creating a broad scientific foundation for continued research into GH and IGF-1 signaling.

Product Reference

Our CJC no DAC 10MG presentation provides a defined modified GHRH research peptide carrying a stated 99.1% purity designation. We document the material according to its 29-amino-acid classification, molecular characteristics, vial configuration, endocrine research applications, and Research Use Only status.

Consequently, the product provides researchers with a clearly identified material for investigating GHRH receptor activity, pituitary somatotroph signaling, GH secretion, cAMP-associated pathways, and IGF-1-axis research. Furthermore, distinguishing the no-DAC configuration from albumin-binding CJC-1295 formulations allows researchers to maintain clearer molecular and experimental reference points when comparing related GHRH analogs.